-
Purposehuman Ah receptor and Arnt cDNAs expressed under control of Gal1,10 bidirectional promoter
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 112510 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneunknown
-
Vector typeYeast Expression, Synthetic Biology
-
Selectable markersURA3
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberLow Copy
Gene/Insert
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site unknown (unknown if destroyed)
- 3′ cloning site unknown (unknown if destroyed)
- 5′ sequencing primer GAL1 (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
This plasmid contains the human aryl hydrocarbon receptor (AhR) expressed from the GAL1,10 promoter along with ARNT. Together they form a heterodimeric transcription factor.
Use the HpaI site for linearization and integration into yeast chromosome III. This is an integrating vector without a yeast replication origin.
Addgene NGS detected a K298R mutation within the HIF1B translation. The depositing laboratory states that this does not adversely affect protein function
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pIGAhRC was a gift from Charles Miller (Addgene plasmid # 112510 ; http://n2t.net/addgene:112510 ; RRID:Addgene_112510) -
For your References section:
A human aryl hydrocarbon receptor signaling pathway constructed in yeast displays additive responses to ligand mixtures. Miller CA 3rd. Toxicol Appl Pharmacol. 1999 Nov 1;160(3):297-303. doi: 10.1006/taap.1999.8769. 10.1006/taap.1999.8769 PubMed 10544064